Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Trading Statement

3 Oct 2011 07:00

RNS Number : 3414P
Tarsus Group PLC
03 October 2011
 



Tarsus Group plc

3 October 2011

Disposal of French Joint Venture

and

Trading Update

Modamont - France

 

Tarsus Group plc ('Tarsus', the 'Group' or the 'Company'), the international business-to-business media group, is pleased to announce that it has reached agreement to dispose of its 51 per cent. interest in the joint venture, Modamont SAS ("Modamont"), to its joint venture partner, Premiere Vision SAS, for a total consideration of €6.1 million (the "Disposal").

 

Modamont is the leading exhibition for fashion accessories in France and takes place bi-annually in Paris in February and September. In the year ended 31 December 2010 Tarsus's 51 per cent. share of Modamont revenues and profits were approximately €2.2 million and €0.6 million respectively. Tarsus's share of Modamont's net assets were approximately €0.7 million as at 30 September 2011. Tarsus's share of Modamont's gross assets as at 30 June 2011 were approximately €1.5 million. At completion, Tarsus France SAS will repay a loan of €2.2 million to Modamont. The net proceeds from the Disposal will be used to give additional flexibility to the Company's balance sheet.

 

Owing to its significant shareholding in Modamont, Premiere Vision is considered to be a related party for the purposes of the Listing Rules and the Disposal therefore constitutes a related party transaction. Consequently, the Disposal is subject to and conditional upon the approval of shareholders in the Company at a general meeting. Further details of the Disposal and a notice convening a general meeting to approve the Disposal will be sent to Tarsus shareholders in due course.

 

Trading Update

 

Since the announcement of the Group's interim results on 27 July 2011, the Group has held three major exhibitions. Off Price took place in Las Vegas in August 2011 and generated a like-for-like revenue increase of approximately 6 per cent. Modamont and Labelexpo Europe (the second largest show in the Group's portfolio, held in Brussels) both took place in September and produced like-for-like revenue increases of 9 per cent. and over 10 per cent. respectively, both slightly ahead of management's expectations. The Group's largest event in the fourth quarter, the Dubai Airshow, is on track to meet management's expectations.

 

Forward bookings continue to be strong and the Board is increasingly confident of good progress being made this year.

 

Douglas Emslie, Group Managing Director of Tarsus, commented:

 

"The disposal of Modamont will materially reduce our exposure to the lower growth European market and less than 10 per cent. of Group profits will now be generated from France. Tarsus France will continue to focus on its remaining wholly owned portfolio of exhibitions.

 

We now have greater financial flexibility to accelerate our drive into the faster growth emerging markets where we are actively pursuing potential acquisitions. As we continue to execute our growth strategy we anticipate a further significant increase in the proportion of our business coming from the emerging markets".

 

For further information, please contact:

 

Tarsus Group plc:

 

Douglas Emslie, Group Managing Director 020 8846 2700

Dan O'Brien, Group Finance Director 020 8846 2700

 

Media

Madano Partnership:

Matthew Moth 020 7593 4000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUROSRAVAKOAR
Date   Source Headline
12th Jan 20187:00 amRNSTrading Update & launch of next phase of strategy
29th Dec 201710:03 amRNSTotal Voting Rights
13th Dec 20173:22 pmRNSScrip Dividend Circular (the "Circular")
5th Dec 201711:45 amRNSHolding(s) in Company
30th Nov 201710:33 amRNSTotal Voting Rights and Capital
21st Nov 20177:00 amRNSCapital Markets Seminar and Trading Update
14th Nov 20177:00 amRNSSite visit to Dubai Airshow
9th Nov 201710:41 amRNSBlock Listing Six Monthly Return
2nd Nov 20177:00 amRNSChange of Advisers
12th Oct 20177:00 amRNSTrading Statement
26th Sep 20177:00 amRNSAnalyst and Investor Site Visit
22nd Sep 20173:55 pmRNSHolding(s) in Company
12th Sep 20177:00 amRNSExpansion of Mexican Joint Venture
6th Sep 201711:38 amRNSBlock Listing Six Monthly Return
31st Aug 20179:31 amRNSTotal Voting Rights
29th Aug 20173:31 pmRNSDirector/PDMR Shareholding
16th Aug 20174:07 pmRNSHalf-year Report
2nd Aug 20171:38 pmRNSDirector/PDMR Shareholding
31st Jul 20172:42 pmRNSTotal Voting Rights
27th Jul 20175:05 pmRNSDirector/PDMR Shareholding
26th Jul 20177:00 amRNSHalf-year Report
11th Jul 201712:42 pmRNSApplication for Admission
30th Jun 20174:09 pmRNSTotal Voting Rights
21st Jun 201712:13 pmRNSResult of AGM
5th Jun 201711:24 amRNSScrip Dividend Circular
31st May 201710:09 amRNSTotal Voting Rights
19th May 20171:42 pmRNSNotice of AGM
18th May 201712:05 pmRNSHolding(s) in Company
17th May 20177:00 amRNSTrading Update
9th May 20172:45 pmRNSBlock Listing Six Monthly Return
28th Apr 201711:05 amRNSTotal Voting Rights
4th Apr 20175:17 pmRNSHolding(s) in Company
4th Apr 20175:16 pmRNSDirector/PDMR Shareholding
31st Mar 201710:37 amRNSTotal Voting Rights
30th Mar 20176:10 pmRNSDirector/PDMR Shareholding
17th Mar 20172:01 pmRNS2016 Annual Report
16th Mar 20172:29 pmRNSDirector/PDMR Shareholding
15th Mar 20178:41 amRNSHolding(s) in Company
6th Mar 20175:45 pmRNSDirector/PDMR Shareholding
6th Mar 20175:44 pmRNSDirector/PDMR Shareholding
1st Mar 20174:04 pmRNSApplication for Block Listing
1st Mar 20177:00 amRNSFinal Results
8th Feb 201712:19 pmRNSDirector Declaration
1st Feb 201712:02 pmRNSTotal Voting Rights
25th Jan 20177:00 amRNSCompletion of acquisition
17th Jan 201711:14 amRNSApplication for Admission
10th Jan 20177:00 amRNSYear-end Trading Update
30th Dec 20169:03 amRNSTotal Voting Rights
22nd Dec 20167:12 amRNSAcquisition of Hometex
14th Dec 20163:26 pmRNSScript Dividend Circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.